Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Developmental therapeutics

524O - Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours

Date

20 Sep 2020

Session

Proffered Paper - Developmental therapeutics

Presenters

Lillian Siu

Citation

Annals of Oncology (2020) 31 (suppl_4): S462-S504. 10.1016/annonc/annonc271

Authors

L.L. Siu1, D. Wang2, J. Hilton3, R. Geva4, D. Rasco5, A.K. Abraham6, J.F. Markensohn6, L. Suttner6, S. Siddiqi6, R.A. Altura6, C. Maurice-Dror7

Author affiliations

  • 1 Medical Oncology And Hematology, Princess Margaret Cancer Centre, University of Toronto, M5G 1Z5 - Toronto/CA
  • 2 Phase 1 Clinical Trials Program, Henry Ford Hospital, 48202 - Detroit/US
  • 3 Medical Oncology, The Ottawa Hospital and University of Ottawa, K1H 8L6 - Ottawa/CA
  • 4 Oncology, Tel Aviv Sourasky Medical Center, 62431 - Tel Aviv/IL
  • 5 Phase 1, START Center for Cancer Care, 78229 - San Antonio/US
  • 6 Medical Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 7 Oncology, Rambam Health Care Campus, 3109601 - Haifa/IL
More

Resources

Login to access the resources on OncologyPRO.

Abstract 524O

Background

MK-4830 is a novel, first-in-class human IgG4 monoclonal antibody targeting the myeloid-specific ILT4 receptor. MK-4830 catalyzes reprogramming of tumour-associated macrophages, relieving myelosuppression and enhancing T cell function. We present data from the first-in-human phase I dose escalation study (NCT03564691) of MK-4830 and MK-4830 + pembrolizumab (pembro).

Methods

Pts with advanced solid tumours received MK-4830 IV Q3W at escalating doses alone and with pembro. Primary end points were safety and tolerability. PK was a secondary end point; exploratory objectives included ORR per RECIST v1.1, evaluation of receptor occupancy (RO), and immune correlates of response in blood and tumour.

Results

Among 84 pts, 50 received MK-4830 monotherapy; 34 received MK-4830 + pembro. Median age was 62 years; 50% previously received ≥3 lines of therapy. No dose-limiting toxicities were observed; maximum-tolerated dose was not reached. Any-grade AEs were consistent with those common to pembro. Treatment-related AEs were reported in 52% of pts; most were grade 1/2. MK-4830 steady-state serum PK at Ctrough was achieved at the highest dose levels, at which almost all pts had ≥95% blood RO. Preliminary efficacy data show 11 objective responses, with 2 complete responses and 9 partial responses; 1 response was observed in a patient receiving MK-4830 monotherapy. All responses occurred in heavily pretreated pts, 5 of whom had not had a response to prior anti–PD-1 therapy. Responses were durable; some pts received >1 year of treatment. Pre- and on-treatment (n=15) biopsies enabled a preliminary assessment of correlation between RO and immune cell subsets before and during treatment.

Conclusions

This first-in-class MK-4830 antibody targeting ILT4 given as monotherapy and in combination with pembro was well tolerated and showed dose-related evidence of target engagement. Durable responses were observed with both MK-4830 alone and with MK-4830 + pembro in heavily pretreated pts, 5 of whom progressed on prior anti–PD-1 therapies. These initial data support the further development of MK-4830 + pembro for pts with advanced solid tumors.

Clinical trial identification

NCT03564691.

Editorial acknowledgement

Medical writing and/or editorial assistance was provided by Holly C. Cappelli and Dana Francis of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Legal entity responsible for the study

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

L.L. Siu: Honoraria (institution): Arvinas; Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Officer/Board of Directors: AACR; Advisory/Consultancy, Research grant/Funding (institution): Celgene; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca/Medimmune; Advisory/Consultancy: MorphoSys; Advisory/Consultancy: Roche; Research grant/Funding (institution): Roche/Genetech; Advisory/Consultancy: Loxo; Advisory/Consultancy: Oncorus; Advisory/Consultancy, Research grant/Funding (institution): Symphogen; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy, Research grant/Funding (institution): GSK; Advisory/Consultancy: Voronoi; Advisory/Consultancy: Treadwell Therapeutics; Advisory/Consultancy: Tessa; Advisory/Consultancy: Navire; Advisory/Consultancy: Relay Therapeutics; Advisory/Consultancy: Rubius Therapeutics; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Karyopharm; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): Intensity Therapeutics; Research grant/Funding (institution): Mirati, Shattucks, and Avid. R. Geva: Honoraria (self), Travel/Accommodation/Expenses: BMS; Honoraria (self): Lilly; Honoraria (self), Travel/Accommodation/Expenses: Medison; Honoraria (self): Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (self): Janssen; Honoraria (self): Takeda; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self): Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: Bayer; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: BOL Pharma; Travel/Accommodation/Expenses: Merck. D. Rasco: Research grant/Funding (institution): Merck. A.K. Abraham: Full/Part-time employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Shareholder/Stockholder/Stock options: Merck & Co., Inc., Kenilworth, NJ, USA. J.F. Markensohn: Full/Part-time employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Shareholder/Stockholder/Stock options: Merck & Co., Inc., Kenilworth, NJ, USA. L. Suttner: Full/Part-time employment: Merck; Research grant/Funding (self): GlaxoSmithKline. S. Siddiqi: Full/Part-time employment: Merck. R.A. Altura: Full/Part-time employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Shareholder/Stockholder/Stock options: Merck & Co., Inc., Kenilworth, NJ, USA. C. Maurice-Dror: Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: BMS; Speaker Bureau/Expert testimony: MSD; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Medison; Travel/Accommodation/Expenses: Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings